Drugs / QRL-101
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07421778 | Feb → Aug 2026 overdue | — | QurAlis Corporation | Recruiting | No outcome recorded |
| Phase 1 | NCT06877624 | Jan → May 2025 | — | QurAlis Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06714396 | Nov 2024 → Aug 2025 | amyotrophic lateral sclerosis | QurAlis Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06681441 | Oct → Dec 2024 | — | QurAlis Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06532396 | Jul → Dec 2024 | — | QurAlis Corporation | Completed | No outcome recorded |
| Phase 1 | NCT05667779 | Dec 2022 → Dec 2023 | — | QurAlis Corporation | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-12-29 | QurAlis Corporation | Results QurAlis Confirms Signal of Target Engagement in ALS Patients in Phase 1 Clinical Trial of QRL-101, a Potentially Best-in-Class Selective Kv7.2/7.3 Ion Channel Opener quralis.com ↗
QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced topline data from its Phase 1 proof-of-mechanism (PoM) clinical trial of QRL-101 in people living with amyotrophic lateral sclerosis (ALS). |
| 2025-12-02 | QurAlis Corporation | Results QurAlis to Present Data From its Phase 1 Clinical Trial of QRL-101, a Potential Best-in-Class Selective Kv7.2/7.3 Ion Channel Opener, at American Epilepsy Society 2025 Annual Meeting quralis.com ↗
The study shows evidence of brain penetration, target engagement, and potential anti-seizure effects demonstrated through biomarkers for transcranial magnetic stimulation electromyography (TMS-EMG) and electroencephalography (EEG). |
| 2025-03-12 | QurAlis Corporation | Results QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers quralis.com ↗
Topline results demonstrated a dose-dependent, statistically significant decrease in motor nerve excitability threshold tracking (mNETT) strength-duration time constant (SDTC), the co-primary endpoint of the trial related to ALS. |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QRL-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06877624 ↗ |
| Route | Oral | “Single-ascending doses of QRL-101 will be orally administered.” NCT05667779 ↗ |